Vt

Current Location

45 Vt Trials Near You

Power is an online platform that helps thousands of Vt patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Cardiac Radioablation vs Catheter Ablation for Rapid Heartbeat

Columbus, Ohio
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

380 Participants Needed

Cryoablation for Ventricular Tachycardia

Columbus, Ohio
This trial is testing a device that uses extreme cold to treat patients with a specific type of irregular heartbeat. It targets patients who have not responded to other treatments by freezing problematic heart tissue to stop abnormal signals.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

206 Participants Needed

mCRM Therapy System for Ventricular Arrhythmias

Columbus, Ohio
The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

297 Participants Needed

Vascular Stent for Venous Obstruction

Columbus, Ohio
This trial tests a small tube called the GORE® VIAFORT Vascular Stent to help adults with blocked veins. The stent keeps the veins open so blood can flow properly.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

111 Participants Needed

CCM Device for Heart Failure

Columbus, Ohio
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%). Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

VTX958 for Crohn's Disease

Columbus, Ohio
This trial is testing a new medication called VTX958 to help people with moderate to severe Crohn's Disease. The goal is to see if it can reduce inflammation in the intestines and improve symptoms. The study will involve several phases over a period of up to three years.

Trial Details

Trial Status:Active Not Recruiting

132 Participants Needed

Vascular Stent for Deep Vein Thrombosis

Cincinnati, Ohio
This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic iliofemoral venous obstruction.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

165 Participants Needed

CRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia

Cincinnati, Ohio
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

12 Participants Needed

ClotTriever vs Anticoagulation for Deep Vein Thrombosis

Edgewood, Kentucky
This trial compares the effectiveness of the ClotTriever System, which removes blood clots from veins, to standard blood-thinning medication in patients with symptomatic blood clots in one leg. The ClotTriever System, developed by Inari Medical, is a mechanical device used to treat deep vein thrombosis (DVT) by removing blood clots from veins.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

Sphere-9 Catheter for VT

Cleveland, Ohio
Sphere-9 VT is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

20 Participants Needed

AI-Guided Ablation for Ventricular Tachycardia in Heart Disease

Cleveland, Ohio
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

100 Participants Needed

Pulse Field Ablation for Ventricular Tachycardia

Cleveland, Ohio
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with FlexAbility SE or ThermoCool ST catheter for ablation of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

40 Participants Needed

Blood Thinners for Pulmonary Embolism Prevention After Hip and Knee Replacement

Cleveland, Ohio
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:21+

20000 Participants Needed

Abelacimab vs Apixaban for Cancer-Related Blood Clots

Cleveland, Ohio
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1655 Participants Needed

Apple Watch Monitoring for Glioblastoma

Cleveland, Ohio
This trial uses the Apple Watch and an iPhone app to monitor glioblastoma patients' health data continuously. The goal is to detect early signs of complications by analyzing patterns in heart rate, breathing, movement, and sleep. This could help predict problems before they happen. The Apple Watch has been increasingly integrated into health care for monitoring heart rate and other health metrics, with studies suggesting its potential usefulness in detecting conditions like atrial fibrillation and monitoring cardiac health.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

25 Participants Needed

Thrombectomy System for Blood Clots in Lungs

Cleveland, Ohio
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

125 Participants Needed

Aspirin vs LMWH for Blood Clot Prevention in Orthopaedic Cancer Surgery

Cleveland, Ohio
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 4

2868 Participants Needed

Percutaneous Mechanical Thrombectomy for Deep Vein Thrombosis

Morgantown, West Virginia
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

60 Participants Needed

Rivaroxaban for Cancer-related Blood Clot Prevention

Windsor, Ontario
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1828 Participants Needed

Pharmacist Alerts for Blood Clot Management

Ann Arbor, Michigan
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral option is associated with a higher rate of prescription changes for initial-prescription alerts that are directed to the prescriber at the time of initial-prescribing errors. Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high risk medications, including anticoagulants
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

306 Participants Needed

Why Other Patients Applied

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

DR-01 for Alopecia Areata and Vitiligo

Indianapolis, Indiana
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

80 Participants Needed

Perioperative Anticoagulant Management for Atrial Fibrillation

Detroit, Michigan
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure involving neuraxial anesthesia. The purpose of the PAUSE 2 study is to show that PAUSE management will be as safe (i.e., non-inferior) as ASRA management, with 95% of patients having low/undetectable pre-operative DOAC levels \<30 ng/mL in each group., at the time of surgery/neuraxial.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

920 Participants Needed

Radiation Therapy for Ventricular Tachycardia

Royal Oak, Michigan
The goal of this interventional study is to determine the minimum dose necessary for successful cardiac radioablation of refractory ventricular tachycardia (VT) and to study the utility of target volume definition using Delayed Enhancement Cardiac MRI (DE-CMR) .
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

24 Participants Needed

Imaging for Ventricular Tachycardia

London, Ontario
The purpose of this study is to (1) determine whether computed tomography (CT) imaging can be used to identify areas of ischemic scar, which are often used as radiation targets for cardiac radioablation, just as well as MRI can, and (2) to determine how best to deliver cardiac radioablation treatment to a patient, for example, which treatment machine should be used and how to limit the effect of chest movement during treatment. Participants will undergo two separate imaging appointments: one CT imaging appointment, where they will undergo scans including perfusion scans, late enhancement scans, and radiation therapy treatment planning scans; and one MRI appointment, where they will undergo scans including a late enhancement scan. The overlap in areas of ischemic scar as identified in CT scans and MRI scans will be quantified. Using radiation therapy treatment planning CT scans, the safety and feasibility of different treatment and motion management techniques will be evaluated. Treatment plans will be created using these different techniques and will be compared to one another. These plans will also be evaluated for compliance with dose constraints.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

15 Participants Needed

Rivaroxaban vs Apixaban for Blood Clots

London, Ontario
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada. No safety or efficacy data is available from direct head-to-head comparison of these two anticoagulants. Lawsuits in the United States over bleeding events, patient perceptions, and concerns with medication adherence are additional factors highlighting the importance of a comparison trial. This multi-center, pragmatic, prospective, randomized, open-label, blinded end-point (PROBE) trial aims to compare the safety of apixaban and rivaroxaban for the treatment of VTE.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

2760 Participants Needed

REGN9933 + REGN7508 for Venous Thromboembolism

London, Ontario
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

195 Participants Needed

PEFA Ablation Technique for Ventricular Tachycardia

London, Ontario
This trial tests a new procedure that uses a special technique to find and fix areas in the heart causing dangerous rhythms in patients with heart disease and previous heart attacks. The goal is to reduce life-threatening heart rhythm problems better than current treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:19+

40 Participants Needed

VTX2735 for Pericarditis

Owensboro, Kentucky
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 6-week Open Label Treatment period (a participant receives active Dose A), a 7-week Extension Treatment period (a participant meets criteria for continuing and receives active Dose A) and a 14-day Follow-Up Period.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

30 Participants Needed

Statins for Blood Clots

Hamilton, Ontario
The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants). While treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming. The medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study. The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

2700 Participants Needed

Abelacimab vs Dalteparin for Blood Clot Prevention in Cancer Patients

Hamilton, Ontario
This trial compares a new medication, Abelacimab, to another treatment, Dalteparin, in patients with GI or GU cancer who have had blood clots. The goal is to see which treatment better prevents new clots and reduces bleeding risks.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1020 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Vt clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Vt clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Vt trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Vt is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Vt medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Vt clinical trials?

Most recently, we added Radiation Therapy for Ventricular Tachycardia, Pulse Field Ablation for Ventricular Tachycardia and Imaging for Ventricular Tachycardia to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Babylon, NY

142 Prostate Cancer Trials near Ventura, CA

Top Mitochondrial Disease Clinical Trials

Top Clinical Trials near Burlington, VT

Top Clinical Trials near Bend, OR

11 Bipolar Disorder Trials near Austin, TX

Top Clinical Trials near Iowa

144 Clinical Trials near Hopedale, IL

Top Clinical Trials near Dunmore, PA

183 Clinical Trials near Haughton, LA

Top Clinical Trials near Hibbing, MN

Top Clinical Trials near Daphne, AL

By Trial

Xylitol for Inflammatory Bowel Disease

Durvalumab + Chemotherapy for Breast Cancer

Pegunigalsidase Alfa for Fabry Disease

Bexarotene + Radiotherapy for Cutaneous T-Cell Lymphoma

Statins for Prostate Cancer

Nerve Blocks for Vocal Cord Surgery

Volrustomig + Chemotherapy for Advanced Non-Small Cell Lung Cancer

Endoscopic Sleeve Gastroplasty for Obesity

Methadone for Pain Management in Cardiac Surgery

PCIT + Natural Helpers for Childhood Behavior Issues

Cafe Move for Preventing Frailty in Aging

At-Home Cardiac Rehabilitation for Heart Failure

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial